Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1358894 in MDD with Inadequate Response
NCT04521478Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of bi 1358894 in major depressive disorder (MDD) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 6 weeks. Started Nov 2020; status: completed.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04521478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521478.